(19) World Intellectual Property Organization

International Bureau



1 (1888 BILLION DE CONTRETA DE LA BERLA DE LA PRESENTA DE LA CONTRETA DE LA CONTRETA DE LA CONTRETA DE LA CONT

(43) International Publication Date 30 June 2005 (30.06.2005)

(10) International Publication Number WO 2005/058898 A3

- C07D 473/00. (51) International Patent Classification7: A61K 31/52
- (21) International Application Number:

PCT/IB2004/004173

(22) International Filing Date:

16 December 2004 (16.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

16 December 2003 (16.12.2003) 60/529,824

- (71) Applicant (for all designated States except US): RAN-BAXY LABORATORIES LIMITED [IN/IN]; 19, Nehru Place, New Delhi, Delhi 110019 (IN).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): PALLE, Venkata, P. [IN/IN]; D-011, Oakwood Estate, Akashneem Marg, DLF Phase II, Gurgaon, Haryana 122001 (IN). BAL-ACHANDRAN, Sarala [IN/IN]; A-6, National Institute of Immunology, Aruna Asif Ali Marg, New Delhi, Delhi 110067 (IN). SALMAN, Mohammad [IN/IN]; P - 2/19, DLF City, Phase - II, Gurgaon, Haryana 122001 (IN). KUKREJA, Gagan [IN/IN]; LD-166, Pitampura, Delhi, Delhi 110088 (IN). BAREGAMA, Lalit, Kumar [IN/IN]; Chyawan-Bhavan, Adarsh Nagar, Kapasan, Rajasthan 312202 (IN). RAY, Abhijit [IN/IN]; Sector C-1, Flat No. 1408, Vasant Kunj, New Delhi, Delhi 110044 (IN). DASTIDAR, Sunanda, Ghosh [IN/IN]; B-138, Sarita Vihar, New Delhi, Delhi 110044 (IN).

- (74) Common Representative: RANBAXY LABORATO-RIES LIMITED; c/o DESHMUKH, Jay R., 600 College Road East, Suite 2100, Princeton, NJ 08540 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 11 August 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PURINE COMPOUNDS WHICH CAN BE USED AS PHOSPHODIESTERASE (PDE) TYPE IV INHIBITORS

(57) Abstract: The present invention relates to purine derivatives, which can be used as selective phosphodiesterase (PDE) type IV inhibitors. Compounds disclosed herein can be useful in the treatment of asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Also provided are processes for the preparation of disclosed compounds, pharmaceutical composition containing the disclosed compounds and their use as selective phosphodiesterase (PDE) type IV inhibitors.